# US 2021/0341482 A1 · Cancer biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341482 A1
- Document ID: US20210341482A1
- Status: Published application
- Kind: A1
- Application number: 17/041,964
- Filed: 2019-05-14
- Published: 2021-11-04
- Earliest claimed: 2018-05-15
- Applicants: Nottingham University Hospitals Nhs Trust
- Inventors: Tarek ABDEL-FATAH; Stephen CHAN
- Web page: https://patentgrep.com/patent/US20210341482A1

## CPC

- G01N 33/57515: of the breast
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to a method for determining if a cancer of a subject is expected to respond to chemotherapy.

## Claims

### Claim 1

A method for determining if a cancer of a subject is expected to respond to chemotherapy, the method comprising:
(i) determining if a cell in a sample of the cancer expresses granules of SPAG5 protein; and/or
(ii) determining if cells in a sample of the cancer overexpresses a SPAG5 transcript;
wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if the sample overexpresses the SPAG5 transcript, the subject has a cancer that is expected to respond to chemotherapy;
wherein if the sample does not comprise a cell that expresses granules of SPAG5 protein and/or if cells in the sample does not overexpress the SPAG5 transcript, the subject has a cancer that is not expected to respond to chemotherapy.

### Claim 2 (depends on 1)

The method claim 1, further comprising the step of determining that a cell in a sample of the tumour is ER+, wherein if a cell in a sample of the tumour is ER+ and the sample comprises a cell that expresses granules of SPAG5 protein and/or the sample overexpresses the SPAG5 transcript, the tumour is expected to respond to chemotherapy, and wherein if the sample comprises a cell that is ER+ and the sample does not comprise a cell that expresses granules of SPAG5 protein and/or the cells in the sample do not overexpress the SPAG5 transcript, the tumour is expected respond to endocrine therapy.

### Claim 3

A method for determining if an ER+ cancer of a subject is expected to respond to endocrine therapy or chemotherapy, the method comprising:
(i) determining if a cell in a sample of the ER+ cancer expresses granular SPAG5 protein; or
(ii) determining if cells in a sample of the ER+ cancer overexpress a SPAG5 gene;
wherein if the sample does not comprise a cell that expresses granular SPAG5 protein and/or if cells in the sample do not overexpress SPAG5 transcript, the subject has a cancer that is expected to respond to endocrine therapy, and
wherein if the sample comprises a cell that expresses granular SPAG5 protein and/or if cells in the sample overexpress the SPAG5 transcript, the subject has a cancer that is expected to respond to chemotherapy.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

A method according to any one of the preceding claims, wherein if the sample does not comprise a cell that expresses granules of SPAG5 protein and/or cells in the sample do not overexpress the SPAG5 transcript, the cancer is expected to be resistant to chemotherapy.

### Claim 7

A method according to any one of the preceding claims, wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if cells in the sample overexpress the SPAG5 transcript, the cancer is expected to be resistant to endocrine therapy.

### Claim 8

A method according to any one of the preceding claims, wherein if the sample comprises a cell that is ER+ and comprises a cell that expresses granules of SPAG5 protein and/or if cells in the sample overexpress the SPAG5 transcript, the tumour is expected to respond to anthracycline-based combination chemotherapy and/or taxane.

### Claim 9

A method of treating cancer in a subject with chemotherapy or endocrine therapy, the method comprising:
(a) determining if the subject has an ER+ cancer that is expected to respond to endocrine therapy or chemotherapy, and
(b)(i) if the ER+ cancer is expected to respond to endocrine therapy, administering a therapeutically effective amount of endocrine therapy to the subject in order to treat the cancer, or
(b)(ii) if the ER+ cancer is expected to respond to chemotherapy, administering a therapeutically effective amount of chemotherapy to the subject in order to treat the cancer.

### Claim 10 (depends on 3, 6, 7, 10)

A method according to claim 10, wherein determining if the ER+ tumour is expected to respond to endocrine therapy comprises the method of any one of claims 3, 6 or 7.

### Claim 11 (depends on 11)

The method according to claim 11, further comprising repeating step (a), after step (b)(i) or (b)(ii), to determine if it is appropriate for the subject to be treated with the same cancer therapy or if a different cancer therapy should be administered, optionally wherein a repetition of step (a) occurs after a relapse of the cancer.

### Claim 12 (depends on 11)

The method according to claim 11, further comprising repeating step (a), after step (b)(i) or (b)(ii), followed by performing step (b)(i) or step (b)(ii), optionally, wherein a repetition of step (a) and performance of step (b) occurs after a relapse of the cancer.

### Claim 13

A method of treating cancer in a subject with chemotherapy or endocrine therapy, the method comprising:
(a) administering a therapeutically effective amount of an endocrine therapy to a subject who has a ER+ cancer, wherein the cells of the cancer do not comprise granules of SPAG5 protein and/or the cells do not overexpress SPAG5 transcript, in order to treat the cancer, or
(b) administering a therapeutically effective amount of chemotherapy to a subject who has a ER+ cancer, wherein a cell of the cancer comprises granules of SPAG5 protein and/or the cells overexpress SPAG5 transcript, in order to treat the cancer.

### Claim 14

A method of determining the efficacy of treating a subject suffering from cancer with a cancer therapy, the method comprising:
(i) determining the percentage of cells that express granules of SPAG5 protein in a test sample of a cancer from a subject, and
(ii) comparing the percentage of cells that express granules of SPAG5 protein in the test sample with a percentage of cells that express granules of SPAG5 protein in a reference sample,
wherein if the percentage of cells that express granules of SPAG5 protein in the test sample is lower compared to the reference sample, it is indicative of the efficacy of treating the subject with the cancer therapy, and
wherein if the percentage of cells that express granules of SPAG5 protein in the test sample is higher compared to the reference sample, it is indicative of the inefficacy of treating the subject with the cancer therapy.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the determining step is performed using flow cytometry or immunohistochemistry.

### Claim 16 (depends on 14, 15)

The method according to claim 14 or claim 15, wherein the cancer is an ER+ cancer or wherein the cancer is a HER2+ cancer or a cancer that comprises cells that express the HER2.

### Claim 17

A method of determining the prognosis of a subject that has a cancer, the method comprising:
(i) determining if a cell in a sample from the cancer expresses granules of SPAG5 protein; and/or
(ii) determining if cells in a sample from the cancer overexpress a SPAG5 transcript;
wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if cells in the sample overexpress the SPAG5 transcript, the subject has a poor prognosis.

### Claim 18 (depends on 17)

The method according to claim 17, further comprising determining if a cell in the sample from the tumour of the subject is ER+, wherein if a cell in the sample from the tumour is ER+ and the cell expresses granules of SPAG5 protein and/or cells in the sample from the tumour overexpress the SPAG5 transcript, the subject has a poor prognosis; or further comprising determining if a cell in the sample from the tumour of the subject is HER2+, wherein if a cell in the sample from the tumour is HER2+ and the cell expresses granules of SPAG5 protein and/or the sample from the tumour overexpresses the SPAG5 transcript, the subject has a poor prognosis.

### Claim 19 (depends on 17, 18)

The method according to claim 17 or 18, wherein a poor prognosis is an increased risk of relapse at 5 or 10 years after receiving surgery and/or cancer therapy for cancer compared to the relapse risk of a reference individual, or wherein a poor prognosis is an increased risk of death from cancer at 5 or 10 years after receiving cancer surgery and/or cancer therapy compared to the relapse risk of a reference individual.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the increased risk of relapse or the increased risk of death is a 1.5-fold increase or greater, 2-fold increase or greater, or 3-fold increase or greater.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the reference individual is one or more individuals with a cancer that does not comprise SPAG5 granules or that does not overexpress SPAG5 transcript.

### Claim at position 22

-24. (canceled)

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method according to any one of claims 1 to 21, the chemotherapy agent for use according to claim 22 or 23, or the endocrine therapy for use according to claim 24, wherein the cancer is selected from the group consisting of: breast cancer; lung cancer; ovarian cancer; gastric cancer; mesothelioma; Malignant Pleural Mesothelioma; uveal melanoma; melanoma; non-melanoma skin cancer; renal cancer; cholangiocarcinomas; cancer of the pleura; abdominal cancer; peritoneal cancer; cancer of the pericardium; head and neck cancers; brain cancer; liver cancer; biliary tract cancer; gastrointestinal cancers, including upper and lower tracts; urothelial cancer; prostate cancer; testicular cancer; cancer of the tunica vaginalis; cervical cancer, sarcoma; lymphoma; and leukaemia.

### Claim 26 (depends on 1)

The method claim 1, further comprising the step of determining that a cell in a sample of the tumour is HER2+, wherein if a cell in a sample of the tumour is HER2+ and the sample comprises a cell that expresses granules of SPAG5 protein and/or the sample overexpresses the SPAG5 transcript, the tumour is expected to respond to chemotherapy, and wherein if the sample comprises a cell that is HER2+ and the sample does not comprise a cell that expresses granules of SPAG5 protein and/or does not overexpress the SPAG5 transcript, the tumour is expected respond to HER2 target therapy alone.

### Claim 27

A method of determining if an HER2+ cancer of a subject is expected to respond to HER2 target therapy or chemotherapy, the method comprising:
(i) determining if a cell in a sample of the HER2+ cancer expresses granular SPAG5 protein; or
(ii) determining if a sample of the HER2+ cancer overexpresses a SPAG5 gene;
wherein if the sample does not comprise a cell that expresses granular SPAG5 protein and/or if the sample does not overexpress SPAG5 transcript, the subject has a cancer that is expected to respond to HER2 target therapy, and
wherein if the sample comprises a cell that expresses granular SPAG5 protein and/or if the sample overexpresses the SPAG5 transcript, the subject has a cancer that is expected to respond to chemotherapy.

### Claim 28

A method of determining if an HER2+ cancer of a subject is expected to respond to HER2 target therapy, the method comprising:
(i) determining if a cell in a sample of the HER2+ cancer expresses granular SPAG5 protein; or
(ii) determining if the sample of the HER2+ cancer overexpresses a SPAG5 transcript;
wherein if the sample does not comprise a cell that expresses granules of SPAG5 protein and/or if the sample does not overexpress the SPAG5 transcript, the subject has a cancer that is expected to respond to HER2 target therapy.

### Claim 29

A method of determining if an HER2+ cancer of a subject is expected to respond to chemotherapy, the method comprising: determining if a cell in a sample of the HER2+ cancer expresses granules of SPAG5 protein, wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if the sample overexpresses SPAG5 transcript, the subject has a cancer that is expected to respond to chemotherapy.

### Claim 30 (depends on 26, 27, 28, 29)

A method according to any one of claims 26 to 29, wherein if the sample does not comprise a cell that expresses granules of SPAG5 protein and/or the sample does not overexpress the SPAG5 transcript, the cancer is expected to be resistant to chemotherapy.

### Claim 31 (depends on 26, 27, 28, 29)

A method according to any one claims 26 to 29, wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if the sample overexpresses the SPAG5 transcript, the cancer is not expected to respond to or benefit from HER2 target therapy.

### Claim 32 (depends on 26, 27, 28, 29)

A method according to any one of claims 26 to 29, wherein if the sample comprises a cell that is HER2+ and comprises a cell that expresses granules of SPAG5 protein and/or if the sample overexpresses the SPAG5 transcript, the tumour is expected to respond to anthracycline-based combination chemotherapy and/or taxane.

### Claim 33

A method of treating cancer in a subject with chemotherapy and or HER2 target therapy, the method comprising:
(a) determining if the subject has an HER2+ cancer that is expected to respond to HER2 target therapy or chemotherapy, and
(b)(i) if the HER2+ cancer is expected to respond to HER2 target therapy, administering a therapeutically effective amount of HER2 target therapy to the subject in order to treat the cancer, or
(b)(ii) if the HER2+ cancer is expected to respond to chemotherapy, administering a therapeutically effective amount of chemotherapy to the subject in order to treat the cancer.

### Claim 34 (depends on 27, 28, 31, 33)

A method according to claim 33, wherein determining if the ER+ tumour is expected to respond to HER2 target therapy comprises the method of any one of claims 27, 28 and 31.

### Claim 35 (depends on 34)

The method according to claim 34, further comprising repeating step (a), after step (b)(i) or (b)(ii), to determine if it is appropriate for the subject to be treated with the same cancer therapy or if a different cancer therapy should be administered, optionally wherein a repetition of step (a) occurs after a relapse of the cancer or failure of disappearance of cancer cells or failure of reducing the tumour growth or volume.

### Claim 36 (depends on 35)

The method according to claim 35, further comprising repeating step (a), after step (b) (i) or (b) (ii), followed by performing step (b)(i) or step (b)(ii), optionally, wherein a repetition of step (a) and performance of step (b) occurs after a relapse of the cancer or failure of disappearance of cancer cells or failure of reducing the tumour growth or volume.

### Claim 37

A method of treating cancer in a subject with chemotherapy or HER2 target therapy, the method comprising:
(a) administering a therapeutically effective amount of an HER2 target therapy to a subject who has a HER2+ cancer, wherein the cells of the cancer do not comprise granules of SPAG5 protein and/or do not overexpress SPAG5 transcript, in order to treat the cancer, or
(b) administering a therapeutically effective amount of chemotherapy to a subject who has a HER+2 cancer, wherein a cell of the cancer comprises granules of SPAG5 protein and/or overexpress SPAG5 transcript, in order to treat the cancer.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the cancer is an ER+ cancer.

### Claim 39

An HER2 target therapy for use in treating an HER2+ cancer in a subject, wherein the cancer cells of the cancer do not comprise granules of SPAG5 protein or do not overexpress SPAG5 transcript.
